Lung: KANDLELIT-007
Trial ID
07190248
Trial Sponsor
Merck Sharp & Dohme LLC
Description: MK1084 in Combination with Subcutaneous Pembrolizumab with Berahyaluronidase Alfa (MK3475A) versus MK3475A in Combination with Pemetrexed/Platinum (Carboplatin or Cisplatin) Chemotherapy as First-line Treatment of Participants with KRAS G12C-Mutant, Advanced, or Metastatic Nonsquamous NSCLC.